Mazziotta, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 761
EU - Europa 311
AS - Asia 193
AF - Africa 46
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.317
Nazione #
US - Stati Uniti d'America 745
SE - Svezia 131
CN - Cina 96
IT - Italia 87
SG - Singapore 58
BG - Bulgaria 37
CI - Costa d'Avorio 28
FR - Francia 21
NG - Nigeria 17
CA - Canada 16
VN - Vietnam 15
HK - Hong Kong 10
DE - Germania 9
GB - Regno Unito 9
TR - Turchia 9
RU - Federazione Russa 6
AU - Australia 5
CZ - Repubblica Ceca 2
ES - Italia 2
IN - India 2
JP - Giappone 2
ET - Etiopia 1
EU - Europa 1
FI - Finlandia 1
GR - Grecia 1
ID - Indonesia 1
IE - Irlanda 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
Totale 1.317
Città #
Chandler 114
Woodbridge 83
Fairfield 76
Ashburn 49
Houston 49
Beijing 41
Seattle 40
Sofia 37
Serra 32
Wilmington 30
Cambridge 29
New York 29
Santa Clara 29
Singapore 29
Abidjan 28
Boardman 22
Princeton 20
Florence 19
Lagos 17
Lawrence 17
Medford 14
Ottawa 14
Ann Arbor 12
Des Moines 12
Hong Kong 10
Dong Ket 7
Istanbul 7
Bremen 6
Dearborn 6
Fuzhou 5
Hebei 5
London 5
Pisa 5
San Diego 5
Sydney 5
Boulder 4
Changsha 4
Jiaxing 4
San Jose 4
Kunming 3
Livorno 3
Nanchang 3
Nanjing 3
Palermo 3
Shanghai 3
Shenyang 3
Brno 2
Capannori 2
Kilburn 2
Los Angeles 2
Ogden 2
Quanzhou 2
Rome 2
Santa Maria A Monte 2
Washington 2
Addis Ababa 1
Almere Stad 1
Arezzo 1
Bandra 1
Baotou 1
Carrara 1
Cedar Knolls 1
Chicago 1
Cincinnati 1
Dallas 1
Delaware 1
Hangzhou 1
Hefei 1
Helsinki 1
Jinan 1
Jinhua 1
Kocaeli 1
Massa 1
Ningbo 1
North York 1
Palo Alto 1
Paris 1
Phoenix 1
Redwood City 1
San Francisco 1
Surabaya 1
Tokyo 1
Toronto 1
Tullamore 1
Turin 1
Vinci 1
Wandsworth 1
Warsaw 1
Wuhan 1
Totale 997
Nome #
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 110
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 105
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 103
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 100
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 93
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 93
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 89
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 80
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 79
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 75
Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia 71
Cytokine Release from Stimulated PBMC after-HSCT: Results of a Post-Transplant Zinc Oral Supplementation Trial (ZENITH). 69
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN DIFFUSE-LARGE B CELL LYMPHOMA: THE TUSCANY EXPERIENCE 67
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 66
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA: THE TUSCANY EXPERIENCE 64
Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice 56
Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review 28
Totale 1.348
Categoria #
all - tutte 4.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.799


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020215 0 0 0 0 21 39 48 26 27 21 28 5
2020/2021117 8 6 4 4 8 13 0 4 16 9 21 24
2021/2022184 7 6 2 10 31 23 2 3 12 9 17 62
2022/2023360 47 65 24 31 43 33 5 32 49 3 26 2
2023/2024141 8 12 25 3 13 31 10 5 2 3 8 21
2024/2025110 1 18 9 47 35 0 0 0 0 0 0 0
Totale 1.348